Its activation triggers senescence and immunogenicity in hormone receptor-positive tumor models such as BT474, MCF7, and HER2 cells, and induces metabolic collapse and stemness inhibition in triple-negative breast cancer (TNBC). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.